Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy

Reviews in Medical Virology

Volumn 16, Issue 5, 2006, Pages 281-287

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HELPER CELL; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LONG TERM CARE; META ANALYSIS; MORTALITY; PROPHYLAXIS; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; ORGAN TRANSPLANTATION; VIRUS REPLICATION;

EID: 33749337524     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.513     Document Type: Review

References (36)

1. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, on behalf of the Valganciclovir and Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplantation 2004; 4: 611-620.
2. Akalin E, Bromberg JS, Shegal V, Ames S, Daly L, Murphy B. 6 months valganciclovir prophylaxis significantly decreases cytomegalovirus infection incidence in thymoglobulin treated transplant patients. Am J Transplant 2004; 4: 495.
3. Jain A, Orloff M, Lansing K, et al. Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegalovirus (CMV) infection in liver transplant recipients. Am J Transplant 2004; 4(Suppl. 8): 569.
4. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset CMV disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 9-16.
5. Balfour HH Jr., Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-1387.
6. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir propohylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325-330.
7. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729-1733.
8. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HL, A-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
9. Scholz D, Arndt R, Meyer R. Evidence for an immunosuppressive activity of ganciclovir. Transplant Proc 1994; 26: 3253-3254.
10. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908-1912.
11. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E, on behalf of the Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 10: 1065-1070.
12. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogenic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and preemptive therapy. Bone Marrow Transplant 2006; 26: 736-767.
13. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
14. Small LN, Lau J, Snydman DR. Prophylactic (PRO) and preemptive (PRE) ganciclovir (GCV) have similar efficacies in cytomegalovirus (CMV) prevention: a meta-analysis. (Abstract #V-1396) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
15. Strippoli GFM, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139-145.
16. Kim DH, Won DI, Lee NY, et al. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allegeneic peripheral blood stem cell transplantation. Transplantation 2006; 81: 101-108.
17. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22: 537-549.
18. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180: 247-253.
19. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89-92.
20. Singh N, Gayowski T, Wagener MM, Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005; 79: 85-90.
21. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Efficacy and safety of valganciclovir for the prevention of cytomegalovirus disease in high-risk sero-positive solid-organ transplant recipients. Transplantation (in press).
22. Muñoz V, Castellares C, Muñoz P, et al. Epidemiology of citomegalovirus (CMV) infection in liver transplant recipients (LTR) in Spain: a national survey. (Abstract # K-1813) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
23. Limaye AP, Bakhavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652.
24. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitit C virus sequelae, and mortality) in liver transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79: 1428-1434.
25. Heuman DM, Abou-assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-810.
26. Nebbia G, Mattes FM, Garda-Diaz A, Burroughts AK, Samonakis D, Emery VC. Influence of Cytomegalovirus infection on hepatitis C virus replication in liver transplant patients. (Abstract #V-597) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
27. Rosen HR, Brenner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476-478.
28. Chopra KB, Demetris AJ, Blakolmer D, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76: 1487-1491.
29. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplantation 2002; 8: 362-369.
30. Torre-Cisneros J, Madueno JA, De La Mata M, Gonzalez R, Mino G, Sanchez-Guijo P. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002; 8: 773-780.
31. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent CMV infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860.
32. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723-1728.
33. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187: 1801-1808.
34. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients. Transplantation 1999; 67: S126.
35. Berkman SC, Ashcraft E, Baillie GM, et al. Valganciclovir for CMV prophylaxis in liver transplant recipients: an initial experience. Am J Transplant 2004; 4(Suppl. 8): 358.
36. Gavaldà J, de Otero J, Murio E, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transpl Int 1997; 10: 462-465.